
(AGENPARL) – SILVER SPRING mar 09 maggio 2023 Providing information on managing bioequivalence studies interrupted by the COVID-19 public health emergency
Fonte/Source: http://www.fda.gov/drugs/coronavirus-covid-19-drugs/bioequivalence-studies-submission-andas-during-covid-19-pandemic